Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.

Papp, Kim A; de Vente, Saskia; Zeng, Jiewei; Flack, Mary; Padilla, Byron; Tyring, Stephen K

Papp, Kim A; de Vente, Saskia; Zeng, Jiewei; Flack, Mary; Padilla, Byron; Tyring, Stephen K.

Afiliación

Papp KA; K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada. kapapp@probitymedical.com.
de Vente S; AbbVie Inc., North Chicago, IL, USA.
Zeng J; AbbVie Inc., North Chicago, IL, USA.
Flack M; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Padilla B; AbbVie Inc., North Chicago, IL, USA.
Tyring SK; University of Texas Health Science Center and Center for Clinical Studies, Houston, TX, USA.

Dermatol Ther (Heidelb) ; 11(2): 487-497, 2021 Apr.

Article en En | MEDLINE | ID: mdl-33512666

Palabras clave

Biologic therapy; Interleukin-23; Open-label extension; Psoriasis; Risankizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google